GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
1.2k
c/glp1eu·posted 11 months ago by u/cormac_erdogan

why does nobody talk about EU

Question Receipts ×6 Cold Box ×1

why does nobody talk about EU. If this has been answered properly somewhere, link me and I will delete.

On cross-border prescriptions, since the assumption behind half these threads is wrong.

There are EU rules on the recognition of prescriptions issued in another member state, and they are conditional: the prescription has to meet requirements about its form and content, certain categories are excluded, and pharmacies retain discretion in practice.

The result is that "my prescription will be accepted anywhere in the EU" is not a safe assumption, and members here have discovered it at a counter in another country. If it matters for a trip, check before you travel with the pharmacy and with somebody qualified where you are. Nothing on this board is advice about that, and the rules are national in their application whatever the framework says.

Asked in my own language at a local pharmacy and got a clearer answer in five minutes than a fortnight of forum reading.

The structure that makes this board make sense, once.

Marketing authorisation for these products is granted centrally, which is why the same product exists across the union. Everything after that — whether it is reimbursed, on what criteria, at what price, in what pack size, dispensed under what margin rules — is decided nationally.

So "is it covered" has twenty-seven answers, "what does it cost" has twenty-seven answers plus within-country variation, and only "is it authorised" has one. Almost every argument on this board is two people answering different questions from different countries, both correctly.

Tell me where this is wrong. That is the useful part of posting it.

1,328 up / 127 down91% upvoted48 commentsid xy5tm418 Aug 2025

48 comments

27 in this archive, depth 5

best — the order this archive was captured in

u/zaid_grimaldi184 points·11 months ago

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

replysharereportpermalink
u/lucia_bruun0 points·11 months ago

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

replysharereportpermalink
u/zeynep_weiss1 point·11 months ago

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

replysharereportpermalink
u/nl_verzekering1 point·11 months ago

Cosigning on cross-border prescriptions.

This is the split the whole board depends on. Authorisation is European; payment is national.

replysharereportpermalink
u/tuva_aalto2 points·11 months ago·edited

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

replysharereportpermalink
u/greta_nilsen0 points·11 months ago

Agreed that pharmacy margin regulation explains a lot of the price differences people find mysterious.

Adding the practical step — read your own country’s published criteria. They exist and they are definitive.

replysharereportpermalink
load more comments (2) →
u/rohan_steiner124 points·11 months ago

keep the prescription and the receipt, both matter for claims

replysharereportpermalink
u/cormac_erdoganOP-26 points·11 months ago

What does the local patient information leaflet say?

replysharereportpermalink
u/dario_petrescu106 points·11 months ago

Cross-border prescription recognition exists under EU rules but is conditional and narrower than commonly assumed, with requirements about the prescription’s form and content.

replysharereportpermalink
u/TitrationTortoiseslow and boring71 points·11 months ago

What pack size is that price for?

replysharereportpermalink
u/amira_dumitru71 points·11 months ago

Are you comparing the same presentation, or different pack sizes?

replysharereportpermalink
load more comments (3) →
u/naomi_erdogan61 points·11 months ago

Pack sizes and presentations differ between member states, so a headline price is not comparable until it is normalised to a common quantity.

replysharereportpermalink
u/joaquin_trevino15 points·11 months ago

private pricing varies enormously between neighbouring countries

replysharereportpermalink
u/vikram_asante22 points·11 months ago

a prescription from one member state is not automatically valid in another

replysharereportpermalink
u/cormac_erdoganOP17 points·11 months ago

Assumed a prescription would be honoured across the border. It was not, and the rules are clear once you actually read them.

replysharereportpermalink
u/tove_ogunleye23 points·11 months ago

Disagree. That is one member state’s reimbursement rule and it does not generalise across the union.

replysharereportpermalink
u/nl_verzekering14 points·11 months ago

Disagree.

tove_ogunleye is right about cross-border recognition being narrower than the summaries suggest.

replysharereportpermalink
u/TitrationTortoiseslow and boring4 points·11 months ago

the EMA authorises, member states decide who pays

replysharereportpermalink
u/tobias_vukovic1 point·11 months ago

a shortage in one member state is not a shortage in all of them

replysharereportpermalink
u/cormac_erdoganOP0 points·11 months ago

Have you read the published reimbursement criteria where you are?

replysharereportpermalink
u/jarno_karlsen1 point·11 months ago

Have you read the published reimbursement criteria where you are?

Disagreeing with this bit: that criterion belongs to one member state and is being quoted as general.

replysharereportpermalink
u/fabio_nkemelu1 point·11 months ago

Which member state?

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1eu

European access, country by country: prescription routes, reimbursement reality, pharmacy stock, EMA notices and the fact that "EU rules" is usually a national question wearing a European hat.

32kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/glp1eu rules
  1. Tag your country in the title. Bare "EU" questions get a template reply.
  2. Pricing posts need the date and the currency.
  3. EMA and national agency claims need a citation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.